iSpecimen Approached by Crypto Currency Companies for $200 Million Treasury Discussions Woburn, MA

iSpecimen Approached by Crypto Currency Companies

for $200 Million Treasury Discussions

Woburn, MA - September 4, 2025 - iSpecimen

Inc. (NASDAQ: ISPC), (the "Company"), a technology-enabled company modernizing the way human biospecimens are sourced

for scientific research, today announced an update on its major strategic initiative aimed at integrating digital assets into its business

model. The Company had previously announced that it is pursuing a strategic initiative aimed at integrating digital assets into its business

model, by seeking to build an up to $200 million corporate treasury reserve based on the Solana blockchain ecosystem.

Since announcing its intentions in August, iSpecimen

has been approached by several Crypto currency-related companies that have presented opportunities in tokenized real-world assets as well

as among highly ranked cryptocurrencies. In a parallel path, the Company has continued meetings to build a Solana-based treasury program.

"We are refining our approach to build a

digital asset treasury. While the acquisition of Locked Solana appeals, we recognize there are many opportunities that we continue to

explore," commented Mr. Robert Lim CEO of iSpecimen.

As for Solana, iSpecimen plans to establish a

SOL-based treasury program to diversify the Company's balance sheet and to support long-term growth initiatives. ISPC intends to source

treasury management expertise to assist with policy design, counterparty diligence, execution, custody coordination, risk management,

and reporting. The Company expects to fund the treasury program primarily from capital that may be raised from time to time.

To dive deeper, the Company's planned treasury

program contemplates purchasing SOL (the native token of the Solana network) including, where appropriate, Locked SOL, through over-the-counter

transactions with reputable cryptocurrency institutions. Any such purchases will be made only where legally transferable and following

legal, regulatory, and counterparty due diligence. "Locked SOL" refers to SOL subject to contractual transfer or vesting restrictions;

pricing may reflect a discount to prevailing spot prices to compensate for illiquidity and lock-up risk. The Company may also purchase

unlocked SOL on regulated or reputable venues for liquidity management.

Mr. Lim continued, "We plan to deliver shareholder

value primarily through a buy and HODL strategy as well as by purchasing locked SOL at a discount. We plan for the Solana to be staked

including liquid staking tokenization to increase yields for shareholders in the long-term. Nevertheless, we also plan to partially diversify

our Solana holding and allow a small percentage for spot trading." A HODL strategy is a long-term investment approach in Cryptocurrency

to hold assets even in times of market volatility, rather than trying to time the market by frequently buying and selling.

This press release shall not constitute an offer

to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other

jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities

laws of any such state or other jurisdiction.

iSpecimen (Nasdaq: ISPC) offers an online marketplace

for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to

patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for

specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations.

For more information, please visit www.ispecimen.com.

Safe Harbor Statement

Statements in this press release about future

expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking

statements." These statements include, but are not limited to, statements concerning the development of our company. The words "anticipate,"

"believe," "continue," "could," "estimate," "expect," "intend,"

"may," "plan," "potential," "predict," "project," "should," "target,"

"will," "would" and similar expressions are intended to identify forward-looking statements, although not all

forward-looking statements contain these identifying words. The reader is cautioned not to rely on such forward-looking statements. Such

forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should

consider various factors, including the uncertainty regarding future commercial success; risks and uncertainties associated with market

conditions; risks related to the regulatory environment for cryptocurrency transactions; the Company's ability to develop and maintain

its crypto treasury strategy; and risk relating to the Company's ability to raise capital. These and other factors may cause our

actual results to differ materially from any forward-looking statements. Forward-looking statements are only predictions and actual results

may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors

discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31,

2024, filed with the SEC on April 14, 2025, as well as other SEC filings. Any forward-looking statements contained in this press release

speak only as of the date hereof and, except as required by federal securities laws, iSpecimen specifically disclaims any obligation to

update any forward-looking statement, whether as a result of new information, future events or otherwise.